AI English summary of an SEC filing — figures as filed
Procter & Gamble PGThe company said that for fiscal 2024, net sales for Q4 (April–June) were $20.5 billion, unchanged from the prior year, and that organic sales, which exclude the impacts of foreign exchange and acquisitions and divestitures, rose 2%. Diluted EPS was $1.27, down 7%, while core EPS was $1.40, up 2%.
Key points
AI summaryThe company said that for fiscal 2024, net sales for Q4 (April–June) were $20.5 billion, unchanged from the prior year, and that organic sales, which exclude the impacts of foreign exchange and acquisitions and divestitures, rose 2%. Diluted EPS was $1.27, down 7%, while core EPS was $1.40, up 2%.
P&G said that net sales for fiscal 2024 were $84.0 billion, up 2% from the prior year, and organic sales rose 4%. Diluted EPS was $6.02 (+2% growth), and core EPS was $6.59 (+12% growth). The company said a non-cash charge to impair the Gillette trade name intangible asset and higher non-core restructuring charges partially offset the increase in diluted EPS.
The company said that in fiscal 2024 it generated operating cash flow of $19.8 billion and net earnings of $15.0 billion, and that adjusted free cash flow productivity was 105%. In the same year, it returned $14 billion or more to shareholders, including $9.3 billion in dividend payments and $5 billion in share repurchases.
The company said it expects all-in sales growth of 2 to 4% and organic sales growth of 3 to 5% for fiscal 2025. It also said core EPS is expected to grow 5 to 7% from fiscal 2024 core EPS of $6.59, in a range of $6.91 to $7.05 per share.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
Net sales of $20.5 billion for Q4, organic sales +2%
The company said that for fiscal 2024, net sales for Q4 (April–June) were $20.5 billion, unchanged from the prior year, and that organic sales, which exclude the impacts of foreign exchange and acquisitions and divestitures, rose 2%. Diluted EPS was $1.27, down 7%, while core EPS was $1.40, up 2%.
Source · Based on the filing body and exhibits
Full-year net sales of $84.0 billion, core EPS of $6.59
P&G said that net sales for fiscal 2024 were $84.0 billion, up 2% from the prior year, and organic sales rose 4%. Diluted EPS was $6.02 (+2% growth), and core EPS was $6.59 (+12% growth). The company said a non-cash charge to impair the Gillette trade name intangible asset and higher non-core restructuring charges partially offset the increase in diluted EPS.
Source · Based on the filing body and exhibits
Full-year operating cash flow of $19.8 billion, shareholder returns exceed $14 billion
The company said that in fiscal 2024 it generated operating cash flow of $19.8 billion and net earnings of $15.0 billion, and that adjusted free cash flow productivity was 105%. In the same year, it returned $14 billion or more to shareholders, including $9.3 billion in dividend payments and $5 billion in share repurchases.
Source · Based on the filing body and exhibits
Fiscal 2025 outlook (guidance)
The company said it expects all-in sales growth of 2 to 4% and organic sales growth of 3 to 5% for fiscal 2025. It also said core EPS is expected to grow 5 to 7% from fiscal 2024 core EPS of $6.59, in a range of $6.91 to $7.05 per share.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…